National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Atezolizumab (Tecentriq®) in combination with carboplatin and etoposide for 1L ES-SCLC HTA ID: 19030

Atezolizumab (Tecentriq®) in combination with carboplatin and etoposide is indicated for first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

NCPE Assessment Process Complete
Rapid Review commissioned: 19/08/2019
Rapid Review completed 16/09/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 18/09/2019
Pre-submission consultation with Applicant 16/12/2019
Submission received from Applicant 08/05/2020
Preliminary review sent to Applicant 19/06/2020
NCPE assessment re-commenced 17/07/2020
Preliminary review follow-up sent to Applicant 31/07/2020
NCPE assessment re-commenced 04/08/2020
Factual accuracy check sent to Applicant 04/09/2020
NCPE assessment re-commenced 11/09/2020
NCPE assessment completed 24/09/2020
NCPE assessment outcome The NCPE recommends that atezolizumab in combination with carboplatin and etoposide for the first-line treatment of adult patients with ES-SCLC is not considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.